Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Practical and Flexible Genome Profiling Study Using the Halo-Shape Annealing and Defer-Ligation Enrichment (HANDLE) System: HM-Screen-JAPAN02

Naoko Hosono, Takahiro Yamauchi, Chi Sung-Gi, Hironori Arai, Kentaro Fukushima, Daisuke Ikeda, Satoshi Iyama, Akihiko Gotoh, Takayuki Ikezoe, Chikashi Yoshida, Goichi Yoshimoto, Junya Kanda, Naoto Takahashi, Emiko Sakaida, Kensuke Usuki, Yosuke Minami

Blood (2023) 142 (Supplement 1): 2279.

https://doi.org/10.1182/blood-2023-184546

Published: 2023

Journal Articles

An Open-Label, Multicenter, Single-Arm, Phase I Dose Escalation Study of OP-2100, an Orally Bioavailable Prodrug of Decitabine, for Patients with Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Shinya Kimura, Kensuke Usuki, Tatsuo Ichinohe, Takayuki Ikezoe, Junya Kuroda, Senji Kasahara, Sho Okamoto, Hiromitsu Iizuka, Hiroshi Ureshino, Tatsuro Watanabe, Tokihiro Ro, Kosuke Endo, Yuka Kagawa, Yuki Kurahashi, Toshiki Naito, Takahiro Yamauchi

Blood (2023) 142 (Supplement 1): 6466.

https://doi.org/10.1182/blood-2023-173174

Published: 2023

Journal Articles

NGS Profile and the Mathematical Prediction Model for Venetoclax Combination Therapy in HM-Screen-Japan 02 Study

Tomoaki Ueda, Kentaro Fukushima, Naoki Hosen, Sunggi Chi, Hiroshi Haeno, Goichi Yoshimoto, Hironori Arai, Daisuke Ikeda, Kensuke Usuki, Naoto Takahashi, Naoko Hosono, Takahiro Yamauchi, Takeshi Kondo, Kazuhito Yamamoto, Junya Kuroda, Yosuke Minami

Blood (2023) 142 (Supplement 1): 5761.

https://doi.org/10.1182/blood-2023-180339

Published: 2023

Journal Articles

Evaluation of Hematopoiesis and Disease Status in Patients with Hematologic Malignancies Using Whole-Body Bone Marrow Imaging with 18 F-FLT PET/MRI

Hiroaki Araie, Naoko Hosono, Tetsuya Tsujikawa, Hidehiko Okazawa, Takahiro Yamauchi

Blood (2023) 142 (Supplement 1): 2272.

https://doi.org/10.1182/blood-2023-173237

Published: 2023

Journal Articles

Combining Inotuzumab Ozogamicin (IO) with PARP Inhibitors, Olaparib and Talazoparib, Exerts Synergistic Cytotoxicity By Inhibiting the Repair of IO-Induced DNA Strand Breaks in IO-Resistant ALL Cells

Naoko Ida, Miyuki Okura, Naoko Hosono, Takahiro Yamauchi

Blood (2023) 142 (Supplement 1): 5804.

https://doi.org/10.1182/blood-2023-173907

Published: 2023

Journal Articles

Real-World Data in a Prospective Clinical Observation Study for Newly Diagnosed Adult Acute Lymphoblastic Leukemia, the JALSG ALL-CS-12 : Advanced Age Is a Poor Prognostic Factor

Yoshihiro Hatta, Fumihiko Hayakawa, Etsuko Yamazaki, Tohru Murayama, Takeshi Saito, Satoru Takada, Nobuaki Dobashi, Shuichi Ota, Yasuhisa Yokoyama, Masatsugu Tanaka, Shinya Sato, Shigeki Ohtake, Emiko Sakaida, Yoshinobu Maeda, Takahiro Yamauchi, Itaru Matsumura, Yasushi Miyazaki, Hitoshi Kiyoi

Blood (2023) 142 (Supplement 1): 4199.

https://doi.org/10.1182/blood-2023-178332

Published: 2023

Journal Articles

Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy

Blood (2022) 140 (25): 2754–2756.

https://doi.org/10.1182/blood.2022016963

Published: 2022

Includes: Supplemental data

Journal Articles

A Practice-Oriented Genome Profiling Study with the Novel Halo-Shape Annealing and Defer-Ligation Enrichment (HANDLE) System : HM-Screen-JAPAN02

Blood (2022) 140 (Supplement 1): 10722–10724.

https://doi.org/10.1182/blood-2022-159351

Published: 2022

Journal Articles

Genomic Analysis of NPM1 Mutation and KMT2A ( MLL )-Rearrangement/Amplification in Japanese Patients with Acute Myeloid Leukemia: Hematologic Malignancies (HM)-Screen-Japan 01

Blood (2021) 138 (Supplement 1): 4460.

https://doi.org/10.1182/blood-2021-149425

Published: 2021

Journal Articles

Properties and Distribution of IDH-1/2 Mutations in Acute Myeloid Leukemia By the Comprehensive Genomic Analysis

Blood (2021) 138 (Supplement 1): 4447.

https://doi.org/10.1182/blood-2021-149801

Published: 2021

Journal Articles

Genomic Analysis Focusing on RUNX1-RUNX1T1 in Japanese Patients with AML: HM-Screen-Japan 01

Blood (2021) 138 (Supplement 1): 4464.

https://doi.org/10.1182/blood-2021-148492

Published: 2021

Journal Articles

Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study on Patients with Acute Myeloid Leukemia

Blood (2021) 138 (Supplement 1): 4457.

https://doi.org/10.1182/blood-2021-149960

Published: 2021

Journal Articles

Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 302 Patients with Relapsed or Refractory (r/r) Acute Myeloid Leukemia after Intensive Chemotherapy (ASTRAL-2 Study)

Blood (2021) 138 (Supplement 1): 2344.

https://doi.org/10.1182/blood-2021-147769

Published: 2021

Journal Articles

Clinical Significance of FLT3 Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01

Blood (2021) 138 (Supplement 1): 2313.

https://doi.org/10.1182/blood-2021-146796

Published: 2021

Journal Articles

Combination of Highly Sensitive C-Reactive Protein with R-ISS Is a Novel and Powerful Staging System in Multiple Myeloma

Miyuki Okura, MD, Naoko Ida, MD, Saki Tanaka, Takahiro Yamauchi, MD PhD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-141200

Published: 2020

Journal Articles

Interim Analysis of Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study of Patients with AML

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-139147

Published: 2020

Journal Articles

Genetic Features of AML with MLL-Rearrangement and NPM1 Mutation: An Interim-Analysis of HM-Screen-Japan 01

SungGi Chi, MD PhD, Naoko Hosono, MD PhD, Takahiro Yamauchi, MD PhD, Kentaro Fukushima, MD, Hirohiko Shibayama, MD PhD, Seiichiro Katagiri, MDPhD, Akihiko Gotoh, MD PhD, Motohito Okabe, MD, Takanobu Morishita, MD, PhD, Masamitsu Yanada, MD PhD, Kazuhito Yamamoto, MD PhD, Naohito Fujishima, MD PhD, Naoto Takahashi, MD PhD, Reiki Ogasawara, MDPhD, Takeshi Kondo, MD PhD, Yoshikazu Utsu, MD PhD, Nobuyuki Aotsuka, MD, Yoshimasa Kamoda, MD, Kensuke Usuki, MD PhD, Kanenari Takemura, MD, Yasuyuki Nagata, MD PhD, Takaaki Ono, MD PhD, Tsutomu Kobayashi, MD PhD, Junya Kuroda, MD PhD, Hiroto Horiguchi, MDPhD, Satoshi Iyama, MD PhD, Suguru Fukuhara, MD PhD, Koji Izutsu, MD PhD, Makoto Nakamura, MD PhD, Kazuto Togitani, MD, Kensuke Kojima, MD PhD, Kaoru Yamamoto, MD, Yukinori Nakamura, MD, Makoto Yoshimitsu, MD PhD, Kenji Ishitsuka, MD PhD, Kenichi Miyamoto, MD, Yosuke Minami, MDPhD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-139240

Published: 2020

Journal Articles

Genomic Analysis of FLT3 Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01

Blood (2020) 136 (Supplement 1): 32–34.

https://doi.org/10.1182/blood-2020-137343

Published: 2020

Journal Articles

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

Blood (2020) 135 (24): 2137–2145.

https://doi.org/10.1182/blood.2020004856

Published: 2020

Includes: Supplemental data

Journal Articles

The Effect of Diagnostic Wait Time on the Survival of Patients with Diffuse Large B-Cell Lymphoma Differs Depending on International Prognostic Index

Shin Lee, MD, Negoro Eiju, Morishita Tetsuji, MD PhD, Kei Fujita, MD, Hideaki Yamauchi, MD, Kana Oiwa, MD, Takanori Ueda, MD PhD, Takahiro Yamauchi, MD PhD

Blood (2019) 134 (Supplement_1): 2902.

https://doi.org/10.1182/blood-2019-121527

Published: 2019

NARROW

Practical and Flexible Genome Profiling Study Using the Halo-Shape Annealing and Defer-Ligation Enrichment (HANDLE) System: HM-Screen-JAPAN02

An Open-Label, Multicenter, Single-Arm, Phase I Dose Escalation Study of OP-2100, an Orally Bioavailable Prodrug of Decitabine, for Patients with Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

NGS Profile and the Mathematical Prediction Model for Venetoclax Combination Therapy in HM-Screen-Japan 02 Study

Evaluation of Hematopoiesis and Disease Status in Patients with Hematologic Malignancies Using Whole-Body Bone Marrow Imaging with 18 F-FLT PET/MRI

Combining Inotuzumab Ozogamicin (IO) with PARP Inhibitors, Olaparib and Talazoparib, Exerts Synergistic Cytotoxicity By Inhibiting the Repair of IO-Induced DNA Strand Breaks in IO-Resistant ALL Cells

Real-World Data in a Prospective Clinical Observation Study for Newly Diagnosed Adult Acute Lymphoblastic Leukemia, the JALSG ALL-CS-12 : Advanced Age Is a Poor Prognostic Factor

Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy

A Practice-Oriented Genome Profiling Study with the Novel Halo-Shape Annealing and Defer-Ligation Enrichment (HANDLE) System : HM-Screen-JAPAN02

Genomic Analysis of NPM1 Mutation and KMT2A ( MLL )-Rearrangement/Amplification in Japanese Patients with Acute Myeloid Leukemia: Hematologic Malignancies (HM)-Screen-Japan 01

Properties and Distribution of IDH-1/2 Mutations in Acute Myeloid Leukemia By the Comprehensive Genomic Analysis

Genomic Analysis Focusing on RUNX1-RUNX1T1 in Japanese Patients with AML: HM-Screen-Japan 01

Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study on Patients with Acute Myeloid Leukemia

Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 302 Patients with Relapsed or Refractory (r/r) Acute Myeloid Leukemia after Intensive Chemotherapy (ASTRAL-2 Study)

Clinical Significance of FLT3 Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01

Combination of Highly Sensitive C-Reactive Protein with R-ISS Is a Novel and Powerful Staging System in Multiple Myeloma

Interim Analysis of Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study of Patients with AML

Genetic Features of AML with MLL-Rearrangement and NPM1 Mutation: An Interim-Analysis of HM-Screen-Japan 01

Genomic Analysis of FLT3 Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

The Effect of Diagnostic Wait Time on the Survival of Patients with Diffuse Large B-Cell Lymphoma Differs Depending on International Prognostic Index

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only